CA
NZ
UK
AU
IND
US
…
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Imagion Biosystems is an Australian clinical-stage medical technology company developing magnetic nanoparticle-based imaging solutions for earlier cancer detection and intraoperative guidance. Long-term growth could be driven by positive clinical trial outcomes, regulatory approvals and eventual hospital adoption or licensing of its platform, offering potential to address unmet needs in oncology imaging.
Material risks include clinical or regulatory setbacks, lack of commercial revenue and the need for continued financing, together with competition from established imaging modalities and alternative diagnostics.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -4.35M | -2.50M | -16.01M | -9.81M | -6.02M |
| Net income | -4.31M | -2.07M | -12.47M | -9.81M | -8.64M |
| Selling general administrative | - | 1.74M | 3.58M | 5.52M | 3.76M |
| Selling and marketing expenses | - | 0.88M | 6.70M | - | - |
| Gross profit | -0.01M | 2.26M | -0.28M | 0.47M | 0.23M |
| Reconciled depreciation | - | 0.39M | 1.18M | 1.11M | 0.40M |
| Ebit | -3.58M | -0.75M | -11.49M | -9.81M | -6.02M |
| Ebitda | -3.58M | -0.70M | -10.30M | -8.70M | -5.62M |
| Depreciation and amortization | 0.01M | 0.05M | 1.18M | 1.11M | 0.40M |
| Operating income | -3.58M | -0.76M | -15.63M | -9.81M | -6.02M |
| Other operating expenses | 3.58M | 3.42M | 16.72M | 12.70M | 8.87M |
| Interest expense | 0.85M | 1.14M | 1.13M | 0.00M | 0.00M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.01M | 0.07M | 0.03M | 0.01M |
| Net interest income | - | -1.13M | -1.06M | -0.14M | 0.00M |
| Income tax expense | -0.04M | -0.44M | -3.53M | 0.00M | 2.61M |
| Total revenue | - | 2.67M | 1.08M | 0.47M | 0.23M |
| Total operating expenses | 3.58M | 3.02M | 15.53M | 12.70M | 8.87M |
| Cost of revenue | 0.01M | 0.40M | 5.25M | - | - |
| Total other income expense net | -0.77M | -1.75M | -0.37M | -0.00M | -0.00M |
| Net income from continuing ops | - | -2.07M | -12.47M | -9.81M | -6.02M |
| Net income applicable to common shares | - | -2.07M | -12.47M | -9.81M | -6.02M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Other current assets | 0.15M | 0.11M | 0.30M | 0.13M | 0.17M |
| Total liab | 4.21M | 5.09M | 6.46M | 5.30M | 0.81M |
| Total stockholder equity | -2.16M | -2.28M | -4.69M | 4.68M | 13.31M |
| Other current liab | 0.45M | 0.17M | -5.14M | 0.37M | 0.33M |
| Common stock | 65.96M | 62.54M | 59.31M | 56.83M | 56.83M |
| Capital stock | - | - | - | 56.83M | 56.83M |
| Retained earnings | -71.32M | -67.01M | -68.91M | -55.84M | -46.03M |
| Other liab | - | - | - | 0.00M | 0.00M |
| Cash | 1.85M | 2.67M | 0.23M | 4.45M | 13.39M |
| Total current liabilities | 4.21M | 5.09M | 5.36M | 1.73M | 0.78M |
| Net debt | 0.72M | 0.18M | 6.91M | 0.16M | -13.35M |
| Short term debt | 2.56M | 2.85M | 3.55M | 1.04M | 0.02M |
| Short long term debt total | 2.56M | 2.85M | 7.14M | 4.60M | 0.05M |
| Other stockholder equity | - | - | - | 0.88M | 0.35M |
| Property plant equipment | - | - | - | 4.99M | 0.35M |
| Total current assets | 2.04M | 2.79M | 0.60M | 4.99M | 13.77M |
| Net tangible assets | - | - | - | 4.68M | 13.31M |
| Net receivables | 0.03M | 0.00M | 0.07M | 0.09M | 0.03M |
| Inventory | - | - | - | 0.32M | 0.17M |
| Accounts payable | 1.20M | 2.07M | 1.59M | 0.33M | 0.43M |
| Accumulated other comprehensive income | 3.20M | 2.19M | 4.92M | 3.69M | 2.51M |
| Non current assets total | 0.01M | 0.02M | 3.98M | 4.99M | 0.35M |
| Capital lease obligations | - | - | - | 4.60M | 0.05M |
| Long term debt total | - | - | - | 3.56M | 0.03M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.08M | -0.19M | -0.47M | -0.31M |
| Change to liabilities | - | - | - | 0.00M | 0.08M |
| Total cashflows from investing activities | - | 0.08M | -0.19M | -0.47M | -0.31M |
| Net borrowings | - | 0.72M | 3.50M | -0.96M | -0.36M |
| Total cash from financing activities | 3.24M | 3.61M | 4.29M | -0.96M | 5.15M |
| Net income | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
| Change in cash | -0.82M | 2.44M | -4.22M | -8.95M | 0.19M |
| Begin period cash flow | 2.67M | 0.23M | 4.45M | 13.39M | 13.20M |
| End period cash flow | 1.85M | 2.67M | 0.23M | 4.45M | 13.39M |
| Total cash from operating activities | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Issuance of capital stock | - | 3.13M | 2.38M | 0.00M | 5.51M |
| Depreciation | 0.01M | 0.39M | 1.18M | 1.11M | 0.40M |
| Other cashflows from investing activities | - | 0.08M | 0.00M | 0.04M | -0.09M |
| Change to account receivables | -0.01M | 0.07M | 0.37M | -0.20M | -0.03M |
| Sale purchase of stock | - | 3.13M | 2.38M | 0.00M | -0.01M |
| Other cashflows from financing activities | - | 2.93M | -1.59M | -0.96M | -0.36M |
| Change to netincome | - | - | - | 0.65M | 0.50M |
| Capital expenditures | 0.00M | 0.00M | 0.19M | 0.51M | 0.22M |
| Change in working capital | -0.74M | 0.07M | 2.15M | 2.55M | 2.63M |
| Stock based compensation | - | 0.01M | 0.46M | - | - |
| Other non cash items | 1.00M | 0.32M | 0.36M | 8.70M | 5.62M |
| Free cash flow | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| IBX Imagion Biosystems Ltd |
- -% |
0.01 | - | - | 8.38 | 3.84 | 5.67 | -1.90 |
| SHL Sonic Healthcare Ltd |
0.18 0.91% |
20.06 | 16.16 | 17.21 | 0.90 | 1.15 | 1.36 | 8.10 |
| IDX Integral Diagnostics Ltd |
0.01 0.58% |
1.74 | 28.83 | 15.24 | 0.82 | 0.97 | 1.52 | 9.49 |
| ACL Australian Clinical Labs Ltd |
0.04 1.25% |
3.24 | 26.67 | 16.84 | 0.81 | 3.95 | 1.24 | 5.12 |
| HLS Healius Ltd |
0.01 1.01% |
0.50 | - | 29.24 | 0.26 | 2.08 | 0.94 | 10.14 |
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic resonance; and cancer diagnostics businesses. It develops MagSense, which is in Phase 2 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to magnetic relaxometry. The company has collaboration agreement with Wayne State University to develop optimised MRI sequences which is in Phase 2 study of for the MagSense imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert Romeo Proulx | Exec. Chairman, Pres & CEO | 1958 |
| Mr. Geoff Hollis | CFO & Company Sec. | NA |
| Dr. Yalia Jayalakshmi Ph.D. | Chief Devel. Officer | NA |
| Mr. Robert Romeo Proulx | Interim Executive Chairman | 1958 |
| Mr. Geoff Hollis AGIA, BComm, CA | CFO & Company Secretary | NA |
| Mr. Robert Romeo Proulx | Interim Executive Chairman | 1958 |
| Mr. Geoff Hollis AGIA, BComm, CA | CFO & Company Secretary | NA |
| Mr. Robert Romeo Proulx | Interim Executive Chairman | 1958 |
| Mr. Geoff Hollis AGIA, BComm, CA | CFO & Company Secretary | NA |
| Mr. Robert Romeo Proulx | Interim Executive Chairman | 1958 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...